AUTHOR=Chen Qiuni , Chen Yue , Zhang Yijing , Zhang Lijuan , Chen Kankan , He Zhengmei , Wang Chunling , Yu Liang 

TITLE=Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.846044

DOI=10.3389/fonc.2022.846044

ISSN=2234-943X

ABSTRACT=Background: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia (AML). The more accurate risk stratification can provide better guidance of treatment. platelet-large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear. 
Purposes: This study aims to explore the impact of P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment. 
Methods: In the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used a bio-informatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCRlow and P-LCRhigh groups, and their characteristics were compared between the two groups. 
Results: Results show that P-LCRlow was associated with worse OS than P-LCRhigh patients (median OS, 18.53 months versus 25.77 months, p=0.0057). But there were no statistical differences in PFS between the two groups (p= 0.2001). Results of univariate and multivariate COX proportional hazard analyses adjusted for gender, bone marrow blasts level, platelet count and IPSS scores showed P-LCR was useful in the evaluation of PFS (HR 0.212, 95%CI 0.064-0.702, p=0.011) and OS of MDS (HR 0.464, 95%CI 0.284-0.757, p=0.002). 
Conclusion: This study was the first report showing that P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS.
Keywords: Myelodysplastic syndromes (MDS); platelet-large cell ratio (P-LCR); survival; prognosis; biomarker